GLP-1s and Hair Loss: What the Drug Labels and Studies Actually Show

Why this page exists

Searches for "Ozempic hair loss" and "is GLP-1 hair loss permanent" have climbed fast, and most answers stop at "it's a known side effect". We went back to the manufacturers' own prescribing labels, the trial tables inside them and the studies behind the headlines, to see what is actually known — and what isn't.

What the prescribing labels actually say

Sources: current labels on DailyMed for Wegovy → · Zepbound → · Foundayo → · Ozempic → · Mounjaro → (read September 2026)

Four things stand out when you read the tables rather than the headlines:

1. Placebo is not zero. Women taking placebo in these trials reported hair loss too — 1.3% to 3%, depending on the medicine's trials.
2. The gap between women and men is large and repeats across three different medicines from two manufacturers.
3. Each label ties it to weight reduction. On Wegovy, the higher 7.2 mg dose was reported with hair loss in 5.8% of people against 3.3% on 2.4 mg in the same trials. Zepbound and Foundayo, though, show no clear step up between doses.
4. These are reported side effects, not measurements. No trial counted or photographed hair; the percentages are people who reported hair loss as an adverse event.

On the diabetes labels for Ozempic and Mounjaro, alopecia appears only in the list of reports received after the medicines went on sale — reports that, by definition, can't give a reliable frequency. A 2026 systematic review of 24 studies found semaglutide hair-loss reports were rare below 2 mg a week and more common at the higher doses used for weight management. Read the review →

The real-world risk, in absolute numbers

The study behind the "up to 68% higher risk" headlines was published in the BMJ in July 2026 by a University of Pennsylvania team. It followed adults with type 2 diabetes starting a GLP-1 medicine and compared them with people starting one of two other diabetes drug classes: 12,004 against 15,221 in one comparison, and 11,964 against 11,238 in the other, with average follow-up of two to three years.

After adjustment, the rate of a recorded alopecia diagnosis was:

• 6.91 per 1,000 person-years on a GLP-1 medicine against 5.04 on an SGLT-2 inhibitor (hazard ratio 1.37);
• 6.53 per 1,000 person-years against 3.89 on a DPP-4 inhibitor (hazard ratio 1.68 — the "68%").

Put plainly, that is roughly two to three extra hair-loss diagnoses for every 1,000 people treated for a year. The authors describe the absolute risk as low. Read the study →

The details matter:

• The link was specific to non-scarring hair loss, the category that includes telogen effluvium — shedding triggered by a shock to the body — not scarring or autoimmune forms.
• The association weakened after a statistical check designed to detect hidden bias, though it did not disappear.
• Only hair loss that reached a doctor and was coded counts. The authors note that milder or temporary shedding that never prompted a visit is likely missed.
• It studied people with diabetes, not people using these medicines for weight management alone, and it did not measure how much of the effect runs through weight loss.

Adverse-event databases don't settle it either. An analysis of the global VigiBase database linked semaglutide with more hair-loss reports than expected (read it →), while a four-database analysis found GLP-1 medicines were the most-reported diabetes drug class for hair loss but did not meet its threshold for a formal signal. Read it → Spontaneous reports can show that people are noticing something; they cannot tell you how often it happens.

It follows the weight — and it has been seen before

In 1976, two dermatologists described nine patients in JAMA who developed heavy hair shedding two to five months after starting a vigorous weight-reduction programme, having lost between 11.7 and 24.75 kg. Their hair samples showed 25–50% of hairs in the resting phase. Hair returned within several months, and three of the patients had been through the same thing after more than one successful diet. The authors put it down to severe calorie restriction leaving the growing hair short of energy. Read the report →

Weight-loss surgery produces the same effect far more often. Two meta-analyses put hair loss after bariatric surgery at 57% (18 studies, 2,538 people) (read it →) and 47% (41 studies, 7,044 people). Read it → The first found it more common in younger women, linked to lower zinc, folic acid and ferritin, and becoming less common with longer follow-up.

Those surgery percentages and the drug-trial percentages were collected in different ways, so they should not be compared directly. What connects them is the mechanism the BMJ authors point to: weight loss and changes in nutrition are established triggers for telogen effluvium. The 2026 systematic review found tirzepatide — associated with the greatest weight loss — was the GLP-1 medicine most often linked to it. Read the review →

For how that kind of shedding works, including why it shows up months after the trigger: How much hair loss is normal? →

The nutrition question

Less appetite can mean less of everything. A 2026 review of six studies covering 480,825 adults on GLP-1 medicines reported vitamin D deficiency in 7.5% at six months and 13.6% at twelve, ferritin (iron stores) 26–30% lower than in people on SGLT-2 inhibitors, and more than 60% of users eating less calcium and iron than recommended. The authors are clear that the data are observational and do not prove the medicines cause deficiencies. Read the review →

A 2026 consensus statement from European obesity, dietetic and patient organisations recommends paying attention to protein intake and monitoring micronutrient risk during these treatments. Read the statement →

We are not going to tell you what to take. No study has shown that a particular supplement prevents GLP-1-associated shedding. The useful step is to ask your prescriber whether checking things like iron stores or vitamin D makes sense for you.

Is it permanent?

The honest answer is that nobody has measured it for GLP-1 medicines specifically.

What we do know:

• The BMJ authors describe the non-scarring hair loss linked to these medicines as typically transient.
• The 1976 crash dieters' hair returned within several months.
• In the Zepbound trials, no one on the medicine stopped because of hair loss; one person on placebo did.

What we don't know:

• No study has followed GLP-1 users' hair after stopping the medicine, or tracked recovery in people who keep taking it.
• The picture isn't one-directional. A 2026 review noted some reports of hair improving in pattern hair loss on these medicines, against many more reports of shedding, and called for proper prospective studies — partly so that people don't abandon a beneficial treatment unnecessarily. Read the review →

If you are shedding on a GLP-1 medicine, talk to your prescriber before changing or stopping it.

What about retatrutide?

Searches for "does retatrutide cause hair loss" have surged. Retatrutide is still investigational and legally available only to trial participants.

In Lilly's May 2026 announcement of its first large obesity trial, TRIUMPH-1, people on the highest dose lost an average of 28.3% of their body weight over 80 weeks. The listed common side effects were nausea, diarrhoea, constipation, vomiting, upper respiratory infections, dysesthesia (altered skin sensation) and urinary infections — hair loss was not mentioned. The same release's safety summaries for Zepbound and Foundayo do list hair loss as a common side effect. Read Lilly's release →

A topline announcement lists the most common events, not the full safety table. Until the complete trial data are published, the absence of hair loss from that list tells you very little.

When to get it looked at

See your prescriber or a dermatologist if:

• there are patches, smooth areas, a widening part or a receding hairline;
• your scalp is painful, red or scaly, or hairs are breaking off;
• you are losing eyebrow, eyelash or body hair;
• heavy shedding has continued for more than about six months, or started well before any weight loss;
• you are eating very little, being sick often, or losing weight faster than planned.

It helps to bring a timeline: when you started, each dose change, how much weight you lost and how quickly, and when the shedding began.

Where laser caps fit, and where they don't

We sell a laser cap, so read this with that in mind.

The clinical evidence for low-level laser therapy is in androgenetic, or pattern, hair loss. Shedding triggered by rapid weight loss is a different process, and a laser cap is not the answer to it.

If a clinician tells you there is pattern hair loss as well — something shedding can make more noticeable — that is when a device like ours becomes a reasonable thing to discuss. Pattern hair loss explained →

How much hair loss is normal? → · Laser caps for women → · Why doctors are sceptical of laser caps →

Not intended to diagnose, treat, cure, or prevent any disease. The clinical studies referenced evaluated a clinically studied 650nm wavelength and the low-level laser therapy category broadly. Individual results vary and depend on consistent use over time. The FDA 510(k) clearance (K261253) is held by the manufacturer.